Bahrain Mumtalakat Holding Company (Mumtalakat), the sovereign wealth fund of Bahrain, and Arcapita Group Holdings (Arcapita), announced the sale of their stake in NAS Neuron Health Services L.L.C. (NAS Neuron) to a leading US-based Fortune 500 company
NAS Neuron is a leading provider of outsourced medical claims processing services in the GCC. The successful investment has exceeded target returns over a three-year holding period.
In 2017, Arcapita and Mumtalakat partnered to acquire an equity stake in NAS United Healthcare Services LLC. The consortium supported the company's execution of a series of growth initiatives, including the merger with another major UAE third-party administrator (TPA), Neuron LLC.
NAS Neuron is one of the largest private TPAs of medical claims in the GCC, serving over 1.3 million lives across the GCC region.
Khalid Al Rumaihi, chief executive officer of Mumtalakat, said: “Our strategic partnership with Arcapita enabled us to support and witness NAS Neuron’s progress into one of the leading players in the GCC health sector with a solid management structure, and a clear vision to continue on its growth trajectory.
The positive outcome of the venture is a validation of the robust and sound nature of our collective business strategy, and is in line with our efforts towards maintaining a diverse and sustainable portfolio.”
Atif Abdulmalik, Arcapita’s chief executive officer, said: “The UAE and GCC’s private health insurance market has been undergoing a major transformation over the past few years as governments have sought to shift healthcare expenditures from the public to the private sector.
NAS Neuron has been a beneficiary of this trend and the company has successfully navigated the TPA market by rebalancing its portfolio mix, maintaining a strong technology backbone, and improving operating efficiency.”
“Healthcare and wellness are among Arcapita’s focus areas for both our private equity and real estate platforms given the demographic tailwinds supporting this sector. We plan to continue focusing on defensive sectors that are supported by long-term market fundamentals," Abdulmalik added.
Umair Nizami, Group chief executive officer of NAS Neuron, lauded the success of the company.
"Backed by strong strategic shareholders, including Arcapita and Mumtalakat, we successfully brought together the strengths of NAS and Neuron to benefit the wider healthcare industry,” he noted.